KMS Medisurgi Ltd

Regulation 74(5) status

• Regulation 74(5) not applicable as all shares are in demat form.
• No rematerialisation requests were received during the quarter ended 30 September 2026.

AGM details

• AGM held on 30 September 2026 at 3:00 PM at the registered office; physical meeting.
• Shareholders on record date: 67.
• Remote e-voting period: 27 Sep 2026 to 29 Sep 2026.
• Cut-off date for voting rights: 23 Sep 2026.
• Mode of voting: remote e-voting and ballot at venue.

Resolutions and outcomes

• Adoption of standalone financial statements for year ended 31 March 2026; ordinary.
• Declaration of final dividend of ₹0.05 per equity share; ordinary.
• Re-appointment of Rohan Devang Kanakia as director liable to retire by rotation; ordinary.

Voting results

• Resolution 1 passed; 100% of votes cast in favour.
• Resolution 2 passed; 100% of votes cast in favour.
• Resolution 3 passed; 100% of votes cast in favour.

Director changes

• Rohan Devang Kanakia re-appointed as director, liable to retire by rotation.

AGM Details

• Date/time/mode: 30 Sep 2026, 3:00 p.m., physical meeting with remote e-voting; concluded 3:40 p.m.

Key Resolutions

• Adoption of Financial Statements
• Declaration of Dividend
• Re-appointment of Director Rohan Devang Kanakia (retiring by rotation)

Voting Results

• Adoption of Financial Statements — outcome not disclosed.
• Declaration of Dividend — outcome not disclosed.
• Re-appointment of Director Kanakia — outcome not disclosed.

Dividend Details

• Dividend proposal/approval status not disclosed; amount per share not specified.

Director Changes

• Re-appointment of Rohan Devang Kanakia as Director liable to retire by rotation.

KMS Medisurgi Limited — Trading Window closed from October 1, 2026 until 48 hours after the declaration of the duly approved Financial Results of the Company for the half year ended September 30, 2026.

Financial highlights

• Revenue from operations: ₹1,220.85 lakh; YoY decline 12.4%.
• Total income: ₹1,221.88 lakh.
• PBT: ₹33.04 lakh.
• PAT: ₹24.55 lakh.
• EPS: ₹0.74 per share.
• Final dividend proposed: ₹0.05 per equity share.
• Transfer to reserve: ₹24.55 lakh.
• Shareholders' funds: ₹831.48 lakh; paid-up capital ₹330.00 lakh.
• Cash flow from operations: ₹151.34 lakh.
• Long-term borrowings: ₹77.34 lakh.

Balance sheet & liquidity

• Inventories: ₹253.80 lakh; Trade receivables: ₹322.22 lakh.
• Trade payables: ₹125.90 lakh.
• Cash & cash equivalents: ₹110.47 lakh.
• Current ratio: 5.02x.
• Debt-to-equity: 0.09x.
• DSCR: 2.61x.
• ROE: 2.99%.
• ROCE: 5%.

Audits, governance & risks

• Auditor's report: qualified due to gratuity accounting; stock records incomplete.
• Internal controls: material weakness from stock record reconciliation.
• Board meetings: 5 in year; Audit and Nomination & Remuneration committees.
• Secretarial audit: no remarks; independence declarations issued.
• Contingent liabilities: bank guarantees ₹5.03 lakh; LC ₹1.14 lakh.

Dividend & related-party transactions

• Related party sales: KMS Manufacturing Co. ₹765.99 lakh.
• Related party purchases: KMS Manufacturing ₹2.82 lakh; Dermacare ₹99.72 lakh.
• MD remuneration: ₹14.40 lakh; Company Secretary remuneration: ₹1.60 lakh.

Outlook & strategic initiatives

• Plans to expand with automotive and electrical adhesive tapes.
• India offers growth potential for indigenous medical devices and coatings.

Meeting Details

• Board meeting scheduled for 5 September 2026; time and venue not disclosed.

Key Agenda Items

• To approve the date, time, and venue for convening the 28th AGM.
• To approve the Directors’ Report for the year ended 31 March 2026.
• To approve the Notice convening the 28th AGM.
• To recommend the Company's Financial Statements for year ended 31 March 2026 for adoption.
• To consider and record the MD&A for the year ended 31 March 2026.
• To consider and approve the dates for closure of the Register of Members and Share Transfer Books.
• To consider and recommend final dividend on equity shares for the year ended 31 March 2026.
• To approve appointment of a Scrutinizer for conducting AGM voting.

Other Notes

• Trading window closure details not specified.

Dematerialisation/rematerialisation status

• No dematerialisation/rematerialisation requests were received for the quarter ended 30 June 2026.
• Regulation 74(5) not applicable as the entire holding is in demat form.